Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), today announced the final results of its cash tender ...

Ever wondered how much the faces on your nightly news are actually taking home? Let's just say these top news anchors are ...

Biomarkers such as ring sideroblasts are indicators for response to treatments like luspatercept (Reblozyl). In patients with ...

The Autumn Budget, with its £26 billion tax rise by 2029-30, will “drive an exodus of wealth from Britain,” warned Nigel ...

Myelodysplastic syndrome (MDS) is independently associated with incident cardiovascular disease (CVD), according to a study published online Nov. 10 in the Canadian Journal of Cardiology.

Learn how MDS/CMML-associated lupus differs from classic lupus and why clone-directed therapies may offer better outcomes.

During a live event, Praneeth Baratam, MBBS, discussed the molecular factors that affect staging of lower-risk myelodysplastic syndromes.

Two parallel and complementary studies conducted by the IDIBELL team led by Dr. Alessandra Giorgetti have succeeded in ...

Luspatercept-aamt (Reblozyl) is among National Comprehensive Cancer Network Guideline recommendations for low-risk MDS.

MNV-201 has received orphan drug designation for myelodysplastic syndrome, offering regulatory and financial benefits to encourage its development. The therapy uses Mitochondrial Augmentation ...

FORT MYERS, Fla., Sept. 22, 2025 /PRNewswire/ -- Leveraging its proprietary real-world data, Florida Cancer Specialists & Research Institute, LLC (FCS) has concluded the first study to evaluate the ...

HAIFA, Israel, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial ...